Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d ouble‐blind , randomized controlled trial
Authors' conclusion
The anagliptin BID regimen for the treatment of type 2 diabetes was superior in blood glucose control after dinner to improve glycaemic variability, as indicated by MAGE and TIR, but was equivalent to the QD regimen in terms of HbA1c and FPG.
Study context
- Population
- Patients with T2D treated with metformin alone (6.5% < HbA1c < 8.5%)randomized 1:1
- Participants
- 89 patients
- Comparison
- Anagliptin 100 mg BID vs sitagliptin 100 mg QD
Methodological detailsdouble-blind, multicentre
- Double-blind
- Multicentre
Primary result
As reported in the abstract
Change from baseline in mean amplitude of glycaemic excursion (MAGE) (CGM) · 12 weeks
| Group | Value | P vs baseline |
|---|---|---|
| Anagliptin BID | −30.4 ± 25.6 mg/dl | P < .001 |
| Sitagliptin QD | −9.5 ± 38.0 mg/dl | P = .215 |
Value
Anagliptin BID−30.4 ± 25.6 mg/dl
Sitagliptin QD−9.5 ± 38.0 mg/dl
P vs baseline
Anagliptin BIDP < .001
Sitagliptin QDP = .215
- Anagliptin BID vs Sitagliptin QD: P < 0.05 — decrease significantly greater with anagliptin BID
Further findings
| Outcome | Anagliptin BID | Sitagliptin QD | P value |
|---|---|---|---|
| Change in postprandial TIR after dinner (CGM) · 12 weeks | 33.0% ± 22.0% | 14.6% ± 28.2% | P = 0.009 |
| P vs baseline | P < .001 | P = .014 |
Changes in HbA1c and fasting plasma glucose (FPG)
- No statistically significant differences between groups in changes in HbA1c and FPG
Original publication
Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d ouble‐blind , randomized controlled trial. Diabetes Obes Metab. Published 10 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →